News | January 11, 2023
Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
Subscribe To Our Newsletter & Stay Updated
